MannKind (MNKD) H.C. Wainwright 28th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 28th Annual Global Investment Conference summary
2 Oct, 2026Key catalysts and recent developments
Pediatric approval for Afrezza expands its use to patients six and older, with early adoption showing strong enthusiasm among academic centers and encouraging refill rates.
FUROSCIX ReadyFlow autoinjector launch is generating high physician interest, with order rates surpassing previous device versions and expanding into new prescriber groups.
Phase I-B data for the 201 program in IPF was positive, prompting a redesigned phase II trial with results expected in the first half of 2028.
Commercial execution and market expansion
Focus for the next 12–24 months is on driving net sales for Afrezza and FUROSCIX, and executing on development milestones for the 201 program.
ReadyFlow is expected to broaden the FUROSCIX market by reducing device complexity, attracting both existing and new prescribers in cardiology and nephrology.
Efforts are underway to embed ReadyFlow in hospital discharge protocols, with real-world evidence studies planned to support adoption in the IDN space.
Market access and reimbursement
Pediatric Afrezza launch is supported by a bridge program ensuring initial access for $35, with most patients transitioning to paid coverage after initial scripts.
Reimbursement dynamics for pediatric use mirror the adult market, but broader payer engagement is ongoing due to the expanded product portfolio.
Latest events from MannKind
- ReadyFlow momentum and pipeline expansion underpin growth into 2027 and beyond.MNKD
Jefferies Global Healthcare Conference - ReadyFlow accelerates, pediatric AFREZZA gains traction, and MNKD-201 advances toward phase II.MNKD
UBS Global Biopharma Conference 2026 - Q3 revenue rose 24% as commercial launches advanced, with Q4 profitability expected.MNKD
Q3 2026 - IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification.MNKD
Chardan's 10th Annual Healthcare Conference - Q2 2026 revenue up 43% to $109.4M, driven by Afrezza pediatric and FUROSCIX launches.MNKD
Q2 2026 - Nintedanib DPI showed strong safety and efficient lung delivery in IPF, supporting Phase 2 trials.MNKD
Study result - FDA approved FUROSCIX ReadyFlow, enabling rapid at-home IV-equivalent diuretic therapy.MNKD
FDA announcement - Q4 and FY 2025 revenues surged, driven by FUROSCIX and Afrezza, with major 2026 catalysts ahead.MNKD
Q4 2025 - Q1 revenue up 18% to $78.4M, net income up 24%, driven by Tyvaso DPI and Afrezza growth.MNKD
Q1 2025